EyeCon 2026 Banner

News
Media
Conferences
Events
Publications
CME
Partners
Subscribe
Resources

Opinion|Videos|November 29, 2024

Safety of Advanced Therapies in Clinical Trials vs Real World Experience

Author(s)Lisa J. Faia, MD , David R. Lally, MD, Scott D. Walter, MD, MSc, FASRS

Key Takeaways

Lisa J. Faia, MD asks the panel about their concerns regarding the safety of newer agents for the broad array of retinal vascular diseases, highlighting the similarities and differences between clinical trial outcomes and real-world results.

Episodes in this series

4 experts are featured in this series.

EP. 1 Case 1: Treatment-Naïve Neovascular Age-Related Macular Degeneration

4 experts are featured in this series.

EP. 2 First Line Treatment Decisions for Age-Related Macular Degeneration

4 experts are featured in this series.

EP. 3 Case 2: Diabetic Macular Edema With Severe Vision Loss

4 experts are featured in this series.

EP. 4 MOA and Improved Outcomes: Gaps in Measuring Real-World Results

4 experts are featured in this series.

EP. 5 Case 3: Persistently Active Central Retinal Vein Occlusion

4 experts are featured in this series.

EP. 6 Safety of Advanced Therapies in Clinical Trials vs Real World Experience

4 experts are featured in this series.

EP. 7 Case 4: Neovascular Age-Related Macular Degeneration with Serious Pigment Epithelial Detachment

4 experts are featured in this series.

EP. 8 Final Thoughts on Case Presentations and Advanced Therapies

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Content

(Image credit: Takashi Nishida, MD, PhD) Obstructive sleep apnea and glaucoma: What a 12.5-million-patient data set reveals

Obstructive sleep apnea and glaucoma: What a 12.5-million-patient data set reveals

ByOphthalmology Times Staff Reports

June 24th 2026

Injection Image Credit: AdobeStock/Romas_ph

Bayer acquires Perfuse Therapeutics, partners with Iambic to expand ophthalmology and AI capabilities

ByAbigail Lewis, Content Intern

June 24th 2026

(Image credit: Ophthalmology Times) iOpeners with Nicole Bajic, MD: Nikolina Budimlija, MD, on building a multidisciplinary dry eye clinic in Ireland

iOpeners with Nicole Bajic, MD: Nikolina Budimlija, MD, on building a multidisciplinary dry eye clinic in Ireland

ByNicole Bajic, MD,Nikolina Budimlija, MD

June 23rd 2026

Dipanjan Pan, PhD, FRSC, FAIMBE, FAHA, FACC

ARPA-H funds tear-duct biosensor system for dry eye, systemic disease

ByAbigail Lewis, Content Intern

June 23rd 2026

4 experts are featured in this series

Label Updates and Dosing Flexibility in Retinal Vascular Diseases

ByJonathan Jonisch, MD,Anton Kolomeyer, MD PhD,David A. Eichenbaum, MD, FASRS,Esther Lee Kim, MD

June 22nd 2026

Latest CME

(CME Credit) Navigating Pharmacological Presbyopia Treatment for Enhanced Patient Care

(CME Credit) Navigating Pharmacological Presbyopia Treatment for Enhanced Patient Care

Jacob Lang, OD, FAAO; Selina R. McGee, OD, FAAO; Neda Shamie, MD

(COPE Track) Small Mites, Big Impact: Revolutionizing Demodex Blepharitis Care

(COPE Track) Small Mites, Big Impact: Revolutionizing Demodex Blepharitis Care

Arjan Hura, MD; Neda Shamie, MD; Kristin Barnes, OD

(COPE Credit) Navigating Pharmacological Presbyopia Treatment for Enhanced Patient Care

(COPE Credit) Navigating Pharmacological Presbyopia Treatment for Enhanced Patient Care

Jacob Lang, OD, FAAO; Selina R. McGee, OD, FAAO; Neda Shamie, MD

Neurotrophic Keratitis Insights: An Interactive Corneal Sensitivity Testing Workshop

Neurotrophic Keratitis Insights: An Interactive Corneal Sensitivity Testing Workshop

John D. Gelles, OD, FAAO, FIAOMC, FCLSA, FSLS, FBCLA; John Hovanesian, MD, FACS

(CME Track) Small Mites, Big Impact: Revolutionizing Demodex Blepharitis Care

(CME Track) Small Mites, Big Impact: Revolutionizing Demodex Blepharitis Care

Arjan Hura, MD; Neda Shamie, MD; Kristin Barnes, OD

Retina Updates in Montréal

In-Person + Virtual Event

Retina Updates in Montréal

July 16-17, 2026

PER Global Perspectives: The TROP2-Targeted ADC Landscape in NSCLC and How to Interpret the Evidence

PER Global Perspectives: The TROP2-Targeted ADC Landscape in NSCLC and How to Interpret the Evidence

Solange Peters, MD, PhD; Benjamin P. Levy, MD; Tony S.K. Mok, MD, BMSc, FRCP(C), FRCP(Edin), FHKCP, FHKAM(Medicine), FASCO; Maurice Pérol, MD

Interventional Dry Eye: A Stepwise Treatment & Management Approach

Interventional Dry Eye: A Stepwise Treatment & Management Approach

Mark Schaeffer, OD, FAAO; Mile Brujic, OD, FAAO; Nate Lighthizer, OD, FAAO, FAAOMS; Selina R. McGee, OD, FAAO

Rapid Reviews in Retina™: Emerging Updates from Spring 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

Rapid Reviews in Retina™: Emerging Updates from Spring 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

SriniVas Sadda, MD, FARVO; Nathan Steinle, MD

(CME Track) Rapid Reviews in Retina™: Emerging Updates from Summer 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

(CME Track) Rapid Reviews in Retina™: Emerging Updates from Summer 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

Mark R. Barakat, MD, FASRS; David Eichenbaum, MD, FASRS

(CME Track) A Forward Look at Anti-VEGF Therapies: A Paradigm Shift in Neovascular Retinal Disease Management

(CME Track) A Forward Look at Anti-VEGF Therapies: A Paradigm Shift in Neovascular Retinal Disease Management

David Almeida, MD, PhD, MBA; Margaret A. Chang, MD, MS; Arshad M. Khanani, MD, MA, FASRS; Jessica Randolph, MD

(CME Track) The Evolution of MacTel Management: Integrating Neuroprotective Therapies Into Clinical Practice

(CME Track) The Evolution of MacTel Management: Integrating Neuroprotective Therapies Into Clinical Practice

Dante Pieramici, MD, FASRS; Dean Eliott, MD; Robin A. Vora, MD; Charles C. Wykoff, MD, PhD, FASRS

(CME Track) Community Collaborative Connections™: Optimizing the Collaborative Care of Neovascular Retinal Disease in a New Age of Treatment

(CME Track) Community Collaborative Connections™: Optimizing the Collaborative Care of Neovascular Retinal Disease in a New Age of Treatment

Dilsher Dhoot, MD, FASRS; Jordana G. Fein, MD, MS; Deep Parikh, MD; Xiao-Yi (Ellie) Zhou, MD

(CME Track) Collaborating Across the Continuum™: Best Practices in Patient-Centric Team Management of XLRP

(CME Track) Collaborating Across the Continuum™: Best Practices in Patient-Centric Team Management of XLRP

Ramiro Maldonado, MD; Rebecca Nelson, MS, CGC; Robert A. Sisk, MD, FACS, FASRS

Navigating Advances in Neovascular Retinal Disease: Translating Evidence to Practice in AMD, DME, and RVO

Navigating Advances in Neovascular Retinal Disease: Translating Evidence to Practice in AMD, DME, and RVO

SriniVas R. Sadda, MD, FARVO; Mark R. Barakat, MD, FASRS; David A. Eichenbaum, MD, FASRS

(CME Track) Beyond the Collarette: Empowering Patients in the Management of Demodex Blepharitis

(CME Track) Beyond the Collarette: Empowering Patients in the Management of Demodex Blepharitis

Stephen C. Pflugfelder, MD; Cecelia Koetting, OD, FAAO, DipABO

(COPE Track) Beyond the Collarette: Empowering Patients in the Management of Demodex Blepharitis

(COPE Track) Beyond the Collarette: Empowering Patients in the Management of Demodex Blepharitis

Stephen C. Pflugfelder, MD; Cecelia Koetting, OD, FAAO, DipABO

Navigating Ocular Toxicities: A Multidisciplinary Roadmap for Managing Adverse Events in Targeted Cancer Therapy

Navigating Ocular Toxicities: A Multidisciplinary Roadmap for Managing Adverse Events in Targeted Cancer Therapy

Basil Williams, MD; Maura Di Nicola, MD

Rapid Reviews in Retina™: Emerging Updates from Fall 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

Rapid Reviews in Retina™: Emerging Updates from Fall 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

John Kitchens, MD; Michael W. Stewart, MD

Bridging Regional Challenges in Retinal Disease Management: Applying Advanced Anti-VEGF Therapy in Community Practice - NYC Metro

Bridging Regional Challenges in Retinal Disease Management: Applying Advanced Anti-VEGF Therapy in Community Practice - NYC Metro

Deep Parikh, MD

Bridging Regional Challenges in Retinal Disease Management: Applying Advanced Anti-VEGF Therapy in Community Practice - California

Bridging Regional Challenges in Retinal Disease Management: Applying Advanced Anti-VEGF Therapy in Community Practice - California

Dilsher S. Dhoot, MD, FASRS

When Mites Meet Their Match: Empowering Patients With Targeted Treatment for 𝘋𝘦𝘮𝘰𝘥𝘦𝘹 Blepharitis

When Mites Meet Their Match: Empowering Patients With Targeted Treatment for 𝘋𝘦𝘮𝘰𝘥𝘦𝘹 Blepharitis

Mile Brujic, OD, FAAO; Pierce Kenworthy, OD, FAAO; Blair Lonsberry, MS, OD, MEd, FAAO

The Presbyopia-Correcting and Toric IOL Playbook: Game-Changing Surgical Strategies to Enhance Patient Outcomes

The Presbyopia-Correcting and Toric IOL Playbook: Game-Changing Surgical Strategies to Enhance Patient Outcomes

Uday Devgan, MD, FACS, FRCS

Bridging Regional Challenges in Retinal Disease Management: Applying Advanced Anti-VEGF Therapy in Community Practice - Florida

Bridging Regional Challenges in Retinal Disease Management: Applying Advanced Anti-VEGF Therapy in Community Practice - Florida

Carl J. Danzig, MD, FASRS

Trending on Ophthalmology Times - Clinical Insights for Eye Specialists

Bayer acquires Perfuse Therapeutics, partners with Iambic to expand ophthalmology and AI capabilities

Obstructive sleep apnea and glaucoma: What a 12.5-million-patient data set reveals

Memento Medicines launches with $93 million Series A to advance Tie2-activating bispecific for retinal disease

iOpeners with Nicole Bajic, MD: Nikolina Budimlija, MD, on building a multidisciplinary dry eye clinic in Ireland

Meta's AI glasses for veterans: Canto-Sims, OD on closing the access gap